Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

@article{Papp2018IxekizumabTF,
  title={Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).},
  author={Kim Papp and Craig L. Leonardi and Andrew Blauvelt and K Reich and Neil J. Korman and Mamitaro Ohtsuki and C Paul and Susan G. Ball and Gregory S. Cameron and Janelle Shannon Erickson and Lu Zhang and Lotus Mallbris and Christopher Griffiths},
  journal={The British journal of dermatology},
  year={2018},
  volume={178 3},
  pages={674-681}
}
BACKGROUND Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. OBJECTIVES This analysis represents an overview of the efficacy outcomes from three phase III psoriasis studies. METHODS Data were integrated from the 12-week induction period of three studies in which patients received ixekizumab 80 mg every 2 weeks (IXE Q2W; n = 1169) or every 4 weeks (IXE Q4W; n = 1165) after an initial… CONTINUE READING